{
    "clinical_study": {
        "@rank": "163110", 
        "arm_group": [
            {
                "arm_group_label": "0.12% Chlorhexidine", 
                "arm_group_type": "Experimental", 
                "description": "Bexident\u00ae (0.12% chlorhexidine) solution, applied topically, every 8 hrs."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs."
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the efficacy of prophylaxis with 0.12% chlorhexidine gluconate compared with\n      placebo to prevent ventilator associated pneumonia in children admitted to a pediatric\n      critical care unit."
        }, 
        "brief_title": "Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in Children.", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Mechanical Ventilation for More Than 48 Hours.", 
        "condition_browse": {
            "mesh_term": [
                "Pneumonia", 
                "Pneumonia, Ventilator-Associated"
            ]
        }, 
        "detailed_description": {
            "textblock": "Randomised controlled trial to determine the efficacy of 0.12% chlorhexidine gluconate\n      compared with placebo to prevent ventilator associated pneumonia in children admitted to a\n      pediatric critical care unit."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children aged 1 month to 18 years admitted to the intensive care unit.\n\n          -  Intubated for more than 48 hours.\n\n        Exclusion Criteria:\n\n          -  Clinical or radiological diagnosis of pneumonia previous to the endotracheal\n             intubation.\n\n          -  Allergy to chlorhexidine.\n\n          -  Known immune deficiency.\n\n        Elimination Criteria:\n\n          -  Transfer to another hospital."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01883596", 
            "org_study_id": "HPS-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "0.12% Chlorhexidine", 
                "description": "Bexident\u00ae (0.12% chlorhexidine solution)", 
                "intervention_name": "0.12% chlorhexidine solution", 
                "intervention_type": "Drug", 
                "other_name": "Peridex, Betasept, PerioGard."
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chlorhexidine", 
                "Chlorhexidine gluconate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "jjmtz64@hotmail.com", 
                "last_name": "Jesus J Martinez, MD", 
                "phone": "+52 (667) 7139004", 
                "phone_ext": "274"
            }, 
            "contact_backup": {
                "email": "zluz_isabel@hotmail.com", 
                "last_name": "Luz I Zamudio, MD", 
                "phone": "+52 (667) 7164686"
            }, 
            "facility": {
                "address": {
                    "city": "Culiacan", 
                    "country": "Mexico", 
                    "state": "Sinaloa", 
                    "zip": "80200"
                }, 
                "name": "Sinaloa Pediatric Hospital"
            }, 
            "investigator": {
                "last_name": "Jesus J Martinez, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "2", 
        "official_title": "Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit.", 
        "overall_contact": {
            "email": "jjmtz64@hotmail.com", 
            "last_name": "Jesus J Martinez, MD", 
            "phone": "+52 (667) 7139004", 
            "phone_ext": "274"
        }, 
        "overall_contact_backup": {
            "email": "zluz_isabel@hotmail.com", 
            "last_name": "Luz I Zamudio, MD", 
            "phone": "+52 (667) 7164686"
        }, 
        "overall_official": {
            "affiliation": "Sinaloa Pediatric Hospital", 
            "last_name": "Jesus J Martinez, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Mexico: Secretaria de Salud", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of ventilator associated pneumonia", 
            "safety_issue": "No", 
            "time_frame": "Participants will be followed for the duration of intensive care unit stay, an expected average of 2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01883596"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sinaloa Pediatric Hospital", 
            "investigator_full_name": "Jes\u00fas Javier Mart\u00ednez-Garc\u00eda", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mortality", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of intensive care unit stay, an expected average of 2 weeks"
            }, 
            {
                "measure": "Days of mechanical ventilation", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until the date of death or date of extubation, whichever comes first, an expected average of 2 weeks"
            }, 
            {
                "measure": "Length of stay", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until the date of death or date of discharge from the intensive care unit, an expected average of 2 weeks"
            }
        ], 
        "source": "Sinaloa Pediatric Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sinaloa Pediatric Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}